Bayer and Onyx's cancer treatment Nexavar has failed to show benefit in preventing the return of liver cancer after surgery. The drug is already approved in patients with hepatocellular carcinoma ...

The FDA approval is based on the results of the open-label KEYNOTE-224 trial, which enrolled 104 patients who had relapsed after or were refractory to Bayer’s Nexavar (sorafenib), the first-line ...